Anaplastic ganglioglioma

Anaplastic ganglioglioma (also known as ganglioglioma grade III or malignant ganglioglioma) is a rare, high-grade brain tumor classified as a WHO grade III neoplasm. It belongs to the family of gangliogliomas, which are mixed neuronal-glial tumors composed of both neoplastic ganglion cells (mature neurons) and neoplastic glial cells. The anaplastic variant is distinguished from the more common low-grade ganglioglioma (WHO grade I) by the presence of malignant features in the glial component, including increased mitotic activity, microvascular proliferation, and necrosis. This tumor primarily affects the central nervous system, most commonly arising in the cerebral hemispheres, particularly the temporal lobe, though it can occur in other brain regions and rarely in the spinal cord. Symptoms depend on the tumor's location and size but frequently include seizures (often drug-resistant epilepsy), headaches, focal neurological deficits such as weakness or sensory changes, increased intracranial pressure, and cognitive or behavioral changes. Seizures are the most common presenting symptom, consistent with the temporal lobe predilection of these tumors. Some anaplastic gangliogliomas arise from malignant transformation of a pre-existing low-grade ganglioglioma, while others present de novo as high-grade lesions. The BRAF V600E mutation is frequently identified in gangliogliomas and may also be present in the anaplastic variant, which has therapeutic implications. Treatment typically involves maximal safe surgical resection as the primary intervention, often followed by adjuvant radiation therapy and/or chemotherapy given the aggressive nature of this grade III tumor. The extent of surgical resection is an important prognostic factor. Unlike low-grade gangliogliomas, which generally carry an excellent prognosis, anaplastic gangliogliomas have a significantly worse outcome with higher rates of recurrence and progression. Targeted therapies, including BRAF inhibitors (such as dabrafenib) and MEK inhibitors (such as trametinib), are being explored in cases harboring the BRAF V600E mutation. Overall, the prognosis is guarded, and long-term follow-up with neuroimaging is essential.

Common questions about Anaplastic ganglioglioma